University of Guelph Researchers Unlock the Pain Relief Potential of Cannabis. Cannflavins exhibit anti-inflammatory activity that is thirty times that of Aspirin.

The research was done at the Canadian University of Guelph,  by Prof. Tariq Akhtar, Department of Molecular and Cellular Biology, along with MCB professor Steven Rothstein.

Click on this link to visit the University of Guelph to read their post titled: “U of G Researchers First to Unlock Access to Pain Relief Potential of Cannabis ”.

There are two ways to offer pain relief. One way is to essentially block the pain signals from reaching the Brain. That is how Opioids work. Along with the pain relieve may come Opioid addiction. Tens of thousands of people in the USA and Canada have died from Opioid addiction overdose.

This new research provides an alternative approach to pain relief. Instead of just blocking the pain receptors in the brain, this new approach would reduce the inflation which is the source of the pain. Opioids in contrast have no impact on the inflation, as they only block the pain signals.

The University of Guelph research has found that Cannflavins exhibit anti-inflammatory activity that is thirty times that of Aspirin. Cannflavins are derived from the Cannabis Sativa plant. One aspect of this not mentioned in the research  is the low cost to grow the Cannabis plants and hence potentially reducing the cost of producing the medication from the Cannabis Sativa plants.

Cannflavin A and B are Prenylated Flavonoids that are unique to Cannabis Sativa. So what is Cannabis Sativa?  Cannabis Sativa is a specific variety of Marijuana, Cannabis or sometimes referred to as Weed. Again the researches found that Cannflavins exhibit anti-inflammatory activity that is thirty times that of Aspirin.


Video is courtesy of the uofguelph YouTube channel


Prior to Cannabis being made legal in many US States and Canada and slowly around the Globe, there was little research being done on Cannabis. Why? Since it was illegal one had to jump thru hoops to get permission to do any kind of researched related to Cannabis. Also the variety of Cannabis was limited to what was being produced by a Government Sanctioned grow lab. Many have stated that the strain available for research was more akin to Hemp than Cannabis.

My interest in the Medical Potential for Cannabis varieties was sparked by research done at the University of Madrid by Cristina Sanchez. That research proved that THC, a component of certain varieties of Cannabis, did kill Cancer Cells. THC is the Psycho-Active ingredient of certain strains of Marijuana, which gets you high. Cannabis Sativa is one variety from which one can get THC.

In the following video, Cristina Sanchez presents data showing that whole-plant cannabis extracts (pure THC) are more potent than pure Cannabinoids in producing Anti-Tumor responses in cell culture and animal models of the different sub-types of Breast Cancer.


Video is courtesy of the Medicinal Genomic YouTube channel


Please note that the Prenylated Flavonoids discussed in this new research are “NOT” Psycho-Active and will not get you high.

Click on this link to visit the Science Direct site to read the published finding of the University of Guelph Research titled: “Biosynthesis of Cannflavins A and B from Cannabis sativa L“.

It is because Cannabis was made legal in Canada, that this kind of very important research could be done.

What bothers me is that this new research is based on findings from 1985 from the US Patent 6630507 about the medical potential of components of the Cannabis Plant. That US Patent expired on April 21, 2019 and so now anyone can use this info.

From the Abstract of the US Patent 6630507:

Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes Cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention.


Posted by Vincent Banial